Date 7th April 2023
Celix Pharma announces the launch of Sitagliptin + Metformin tablets.
Celix Pharma is pleased to announce the launch of Sitagliptin/Metformin 50mg/1000mg film-coated tablets on loss of exclusivity in the UK. Sitagliptin/Metformin are supplied in blister (patient) packs containing 56 tablets.
Sitagliptin/Metformin is indicated for type 2 diabetes in adult patients as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin and/or a sulphonylurea. Sitagliptin works by increasing the amount of insulin that the body makes, which is the hormone that controls sugar levels in your blood1. Metformin works by helping to restore body's proper response to the insulin that one naturally produces2.
Commenting on this launch, Subir Kohli, Co-founder & CEO said, “Another Day 1 launch for Celix Pharma, adding to our established franchise of Sitagliptin (mono) on the UK market.”
Shantreddy, Co-founder & COO added, “Extremely pleased with another patent-expiry linked launch. This is Celix Pharma’s 7th Product launch and one of several launches planned in 2023.”
About Celix Pharma Ltd
Celix Pharma is a London-based generic pharmaceutical company founded in 2020 with an overarching goal to bring high quality, affordable, generic medicines with a sustainable supply chain to the UK. Celix Pharma focuses on bridging gaps in the market by identifying product opportunities arising from complexities in development and/or manufacturing, addressing supply disruptions and future patent expiries with a portfolio spanning generics, value-added generics, and hospital specialty products. Celix Pharma’s business model is built around creating a commercially led, customer-focused organization supported with strategic partnerships in R&D and manufacturing.
For more information, visit www.celixpharma.com